ADAM HARTHEIMER: Open Payments
NPI 1235799420 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$493 in 21 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $427 · 2025 $493
Food & beverage: $493
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 8 | $189 |
| GENZYME CORPORATION | 6 | $153 |
| Optinose US, Inc. | 2 | $46 |
| HARMONY BIOSCIENCES LLC | 1 | $29 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Amgen Inc. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: DUPIXENT, Xhance, TEZSPIRE, WAKIX, NUCALA, VOQUEZNA.
Industry payments across MD — which companies pay providers there.
